AlloVir, Inc. (NASDAQ:ALVR – Get Free Report)’s stock price dropped 1.2% during trading on Wednesday . The stock traded as low as $0.49 and last traded at $0.51. Approximately 460,323 shares changed hands during mid-day trading, a decline of 23% from the average daily volume of 600,335 shares. The stock had previously closed at $0.51.
AlloVir Stock Down 2.2 %
The firm has a market cap of $52.01 million, a PE ratio of -0.51 and a beta of 0.59. The business has a 50-day moving average price of $0.69 and a two-hundred day moving average price of $0.74.
AlloVir (NASDAQ:ALVR – Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.10.
Institutional Inflows and Outflows
AlloVir Company Profile
Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.
Read More
- Five stocks we like better than AlloVir
- What is a SEC Filing?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- What Investors Need to Know to Beat the Market
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- What is a buyback in stocks? A comprehensive guide for investors
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with MarketBeat.com's FREE daily email newsletter.